Drug General Information
Drug ID	D0D1FC
Former ID	DPR000069
Drug Name	LY-362884
Indication	Obesity; Type 2 diabetes [ICD9: 250, 250.00, 250.02, 278; ICD10:E08-E13, E11, E66]		Phase 2	[536122]
Company	Eli Lilly
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Beta-3 adrenergic receptor	Target Info	Agonist	[536122]
KEGG Pathway	Calcium signaling pathway
	cGMP-PKG signaling pathway
	Neuroactive ligand-receptor interaction
	Endocytosis
	Salivary secretion
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	Beta3 adrenergic receptor signaling pathway
Reactome	Adrenoceptors
	G alpha (s) signalling events
WikiPathways	Monoamine GPCRs
	Calcium Regulation in the Cardiac Cell
	GPCRs, Class A Rhodopsin-like
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 536122	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
Ref 536122	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.